Tony Butler
Stock Analyst at Rodman & Renshaw
(0.95)
# 3,783
Out of 4,918 analysts
105
Total ratings
32.35%
Success rate
-13.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tony Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Initiates: Buy | $25 | $11.55 | +116.45% | 2 | Dec 20, 2024 | |
| HURA TuHURA Biosciences | Initiates: Buy | $11 | $2.40 | +358.33% | 1 | Dec 19, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $18 | $1.57 | +1,046.50% | 4 | Sep 26, 2024 | |
| MURA Mural Oncology | Initiates: Buy | $15 | $2.34 | +541.03% | 1 | Jun 28, 2024 | |
| LPTX Leap Therapeutics | Initiates: Buy | $8 | $0.31 | +2,514.38% | 1 | Jun 28, 2024 | |
| IPSC Century Therapeutics | Reiterates: Buy | $16 | $0.53 | +2,908.08% | 5 | Aug 10, 2023 | |
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $10 | $0.08 | +12,415.64% | 8 | Aug 10, 2023 | |
| FATE Fate Therapeutics | Reiterates: Buy | $10 | $1.07 | +834.58% | 4 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Buy | $75 | $56.09 | +33.71% | 8 | Aug 8, 2023 | |
| MRUS Merus | Reiterates: Buy | $35 | $65.57 | -46.62% | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $60 | $1.81 | +3,214.92% | 5 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $1.48 | +778.38% | 6 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $8.11 | +516.52% | 5 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.08 | +1,288.89% | 8 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $0.33 | +7,475.76% | 6 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.10 | +1,263.64% | 1 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $9.45 | +5.82% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $2.94 | +478.23% | 2 | Jul 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8.3 → $166 | $5.36 | +2,997.01% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $7.60 | +689.47% | 4 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.11 | +11,274.41% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $0.64 | +837.50% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $360 | $4.13 | +8,627.27% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $5 → $2 | $3.80 | -47.37% | 6 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.82 | +292.67% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $10 | $1.35 | +640.74% | 2 | Feb 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $2.96 | +407.61% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $110 | $11.49 | +857.35% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $960 | $5.08 | +18,797.64% | 1 | Mar 2, 2020 |
Atara Biotherapeutics
Dec 20, 2024
Initiates: Buy
Price Target: $25
Current: $11.55
Upside: +116.45%
TuHURA Biosciences
Dec 19, 2024
Initiates: Buy
Price Target: $11
Current: $2.40
Upside: +358.33%
Biomea Fusion
Sep 26, 2024
Upgrades: Buy
Price Target: $18
Current: $1.57
Upside: +1,046.50%
Mural Oncology
Jun 28, 2024
Initiates: Buy
Price Target: $15
Current: $2.34
Upside: +541.03%
Leap Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $8
Current: $0.31
Upside: +2,514.38%
Century Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $16
Current: $0.53
Upside: +2,908.08%
Adaptimmune Therapeutics
Aug 10, 2023
Reiterates: Buy
Price Target: $10
Current: $0.08
Upside: +12,415.64%
Fate Therapeutics
Aug 9, 2023
Reiterates: Buy
Price Target: $10
Current: $1.07
Upside: +834.58%
CRISPR Therapeutics AG
Aug 8, 2023
Reiterates: Buy
Price Target: $75
Current: $56.09
Upside: +33.71%
Merus
Aug 8, 2023
Reiterates: Buy
Price Target: $35
Current: $65.57
Upside: -46.62%
Aug 7, 2023
Reiterates: Hold
Price Target: $60
Current: $1.81
Upside: +3,214.92%
Aug 7, 2023
Reiterates: Buy
Price Target: $13
Current: $1.48
Upside: +778.38%
Aug 3, 2023
Reiterates: Buy
Price Target: $50
Current: $8.11
Upside: +516.52%
Aug 3, 2023
Reiterates: Buy
Price Target: $15
Current: $1.08
Upside: +1,288.89%
Aug 2, 2023
Reiterates: Buy
Price Target: $25
Current: $0.33
Upside: +7,475.76%
Jul 31, 2023
Initiates: Buy
Price Target: $15
Current: $1.10
Upside: +1,263.64%
Jul 12, 2023
Reiterates: Buy
Price Target: $10
Current: $9.45
Upside: +5.82%
Jul 7, 2023
Reiterates: Buy
Price Target: $17
Current: $2.94
Upside: +478.23%
Jul 3, 2023
Reiterates: Buy
Price Target: $8.3 → $166
Current: $5.36
Upside: +2,997.01%
Jun 7, 2023
Reiterates: Buy
Price Target: $60
Current: $7.60
Upside: +689.47%
Jun 5, 2023
Reiterates: Buy
Price Target: $240
Current: $2.11
Upside: +11,274.41%
Jun 1, 2023
Assumes: Buy
Price Target: $6
Current: $0.64
Upside: +837.50%
Jun 1, 2023
Assumes: Buy
Price Target: $360
Current: $4.13
Upside: +8,627.27%
May 30, 2023
Maintains: Hold
Price Target: $5 → $2
Current: $3.80
Upside: -47.37%
Jan 5, 2023
Initiates: Buy
Price Target: $15
Current: $3.82
Upside: +292.67%
Feb 17, 2022
Downgrades: Neutral
Price Target: $30 → $10
Current: $1.35
Upside: +640.74%
Nov 19, 2021
Initiates: Buy
Price Target: $15
Current: $2.96
Upside: +407.61%
Jun 28, 2021
Maintains: Buy
Price Target: $80 → $110
Current: $11.49
Upside: +857.35%
Mar 2, 2020
Initiates: Buy
Price Target: $960
Current: $5.08
Upside: +18,797.64%